Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Up 53.3% in March

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant increase in short interest during the month of March. As of March 13th, there was short interest totaling 56,970 shares, an increase of 53.3% from the February 26th total of 37,152 shares. Based on an average daily volume of 276,289 shares, the short-interest ratio is presently 0.2 days. Currently, 5.9% of the shares of the company are sold short.

Bluejay Diagnostics Price Performance

Shares of NASDAQ BJDX opened at $1.96 on Monday. The stock has a market capitalization of $1.90 million, a price-to-earnings ratio of 0.00 and a beta of 0.72. The firm’s 50 day simple moving average is $2.47 and its 200-day simple moving average is $4.72. Bluejay Diagnostics has a 12 month low of $1.70 and a 12 month high of $40.80.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its earnings results on Friday, March 6th. The company reported $3.23 earnings per share (EPS) for the quarter.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a research report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has an average rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bluejay Diagnostics stock. Armistice Capital LLC purchased a new position in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 65,000 shares of the company’s stock, valued at approximately $43,000. Armistice Capital LLC owned approximately 9.15% of Bluejay Diagnostics at the end of the most recent quarter. 18.47% of the stock is currently owned by hedge funds and other institutional investors.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.